At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 1, 2026 at 08:00 ET
Cogent Biosciences announced the submission of a New Drug Application (NDA) for bezuclastinib in second-line GIST under the FDA's RTOR program, based on positive Phase 3 PEAK trial results showing a 50% reduction in progression risk and 16.5-month median PFS. The drug combination also demonstrated a 46% objective response rate, significantly outperforming sunitinib monotherapy.
- Submitted NDA for bezuclastinib in imatinib-resistant GIST under FDA's Real-Time Oncology Review (RTOR) program
- Phase 3 PEAK trial showed 50% reduction in risk of progression or death (HR 0.50) vs sunitinib monotherapy
- Median PFS of 16.5 months with bezuclastinib combination vs 9.2 months for sunitinib alone
- Objective response rate (ORR) of 46% vs 26% in control arm
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access